Nova Mentis Life Science Corp.

Equities

NOVA

CA66980V1067

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 03:38:53 2024-04-25 pm EDT			5-day change	1st Jan Change
0.015 ^CAD	0.00%		+50.00%	-25.00%

Apr. 08	Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 26	Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	CI

Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 30, 2023 at 07:05 pm EDT

Nova Mentis Life Science Corp. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was CAD 0.528005 million compared to CAD 0.626934 million a year ago.

Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.

Latest news about Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	Feb. 26	CI
Nova Mentis Life Science Corp. Announces Management Changes	Jan. 03	CI
Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director	Dec. 11	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Nova Mentis Life Science Corp. Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	23-08-29	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Nova Mentis Life Science Corp. Auditor Raises 'Going Concern' Doubt	23-04-24	CI
KGK Science Inc. Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	23-04-18	CI
KGK Sciences Inc. Begins Recruiting Participants, on Behalf of Client Nova Mentis Life Science Corp. in First-Ever Clinical Trial Investigating Effects of Psilocybin on Adults Diagnosed with Fragile X Syndrome	23-04-18	CI
Nova Mentis Life Science Corp. Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	23-04-11	CI
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial	23-02-14	CI
Nova Mentis Life Science Corp. Announces Board Changes	23-01-18	CI
Nova Mentis Receives Health Canada Approval for First-Of-its-Kind Psilocybin Clinical Trial	22-12-22	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Nova Mentis Enters into Research Services Contract with KGK Science for Phase II A Clinical Trial	22-11-17	CI
Nova Mentis Life Science Corp. Produces 1.5 mg Psilocybin Microdose Capsules	22-09-29	CI
Nova Mentis Life Science Corp. Forms A Tactical Partnership with KGK Science Inc. to Develop Its Psilocybin Drug Portfolio in Canada	22-09-15	CI
Nova Mentis Life Science Corp. Completes Production of Psilocybin Microdose Capsules	22-09-15	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Nova Mentis Life Science Corp. and University of Central Florida to Develop Saliva Serotonin Assay	22-06-09	CI
Nova Mentis Life Science Corp. Receives Controlled Substances Export Approval From The U.S. DEA for the Proprietary Psilocybin Drug NM 1001	22-06-07	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-27	CI

Chart Nova Mentis Life Science Corp.

Duration

Period

More charts

Company Profile

Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVA MENTIS LIFE SCIENCE CORP.	-25.00%	1.63M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research